Business
BioInvent to Participate in Upcoming Investor Conference
LUND, SE / ACCESS Newswire / December 18, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, ...
About this update from Bioinvent International Ab
[{"type":"text","content":"LUND, SE / ACCESS Newswire / December 18, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that representatives from the Company management team will participate in the following upcoming investor conferences this January:","length":414,"tagName":"p"},{"type":"text","content":"J.P. Morgan 2026 Healthcare Conference, San Francisco, USFormat: One-on-one meetingsDate: January 12-14","length":105,"tagName":"p"},{"type":"text","content":"15th Annual LifeSci Partners Corporate Access Event, San Francisco, USFormat: One-on-one meetingsDate: January 12-13","length":118,"tagName":"p"},{"type":"text","content":"Sweden Networking Breakfast at J.P. Morgan 2026, San Francisco, USFormat: Panel DiscussionDate and Time: January 12, 7:30 am PT","length":129,"tagName":"p"},{"type":"text","content":"Redeye Fight Cancer event 2026, Stockholm, SwedenFormat: Presentation and Q&ADate: January 21, 2026","length":105,"tagName":"p"},{"type":"text","content":"About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.","length":642,"tagName":"p"},{"type":"text","content":"The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.","length":296,"tagName":"p"},{"type":"text","content":"For further information, please contact:Cecilia Hofvander, VP Investor RelationsPhone: +46 (0)46 286 85 50Email: [email protected]","length":147,"tagName":"p"},{"ty...